Reviewing Tenax Therapeutics Inc. (TENX)’s and Ritter Pharmaceuticals Inc. (NASDAQ:RTTR)’s results

Tenax Therapeutics Inc. (NASDAQ:TENX) and Ritter Pharmaceuticals Inc. (NASDAQ:RTTR) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tenax Therapeutics Inc. N/A 0.00 5.93M -4.12 0.00
Ritter Pharmaceuticals Inc. N/A 0.00 15.57M -3.08 0.00

Table 1 highlights Tenax Therapeutics Inc. and Ritter Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 shows the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Tenax Therapeutics Inc. 0.00% -84.5% -77.3%
Ritter Pharmaceuticals Inc. 0.00% -135% -86.8%

Risk & Volatility

Tenax Therapeutics Inc. has a 1.26 beta, while its volatility is 26.00%, thus making it more volatile than Standard & Poor’s 500. Competitively, Ritter Pharmaceuticals Inc. is 45.00% more volatile than Standard & Poor’s 500, because of the 1.45 beta.

Liquidity

10 and 10 are the respective Current Ratio and a Quick Ratio of Tenax Therapeutics Inc. Its rival Ritter Pharmaceuticals Inc.’s Current and Quick Ratios are 5.1 and 5.1 respectively. Tenax Therapeutics Inc. has a better chance of clearing its pay short and long-term debts than Ritter Pharmaceuticals Inc.

Insider and Institutional Ownership

The shares of both Tenax Therapeutics Inc. and Ritter Pharmaceuticals Inc. are owned by institutional investors at 58.7% and 24.3% respectively. About 16.99% of Tenax Therapeutics Inc.’s share are owned by insiders. Insiders Comparatively, owned 13.5% of Ritter Pharmaceuticals Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Tenax Therapeutics Inc. 9.76% 15.38% -40% -76.11% -87.26% 11.57%
Ritter Pharmaceuticals Inc. 5.89% 10.35% -16.1% -68.84% -73.95% 8.53%

For the past year Tenax Therapeutics Inc. was more bullish than Ritter Pharmaceuticals Inc.

Summary

Tenax Therapeutics Inc. beats Ritter Pharmaceuticals Inc. on 5 of the 6 factors.

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. The companyÂ’s product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. It is also exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing various conditions, including gastrointestinal diseases, immuno-oncology, metabolic, and liver disease. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.